Starpharma Holdings Limited
SPL
Rank in Stocks
#18318
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the... Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Share Price
$0.28379791
Last synced: 2026-11-10
Market Cap
$137.05M
Change (1 day)
-7.87%
Change (1 year)
12.96%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Starpharma Holdings Limited (SPL)
Category
Healthcare
EPS for Starpharma Holdings Limited (SPL)
EPS as of June 2026 TTM: $-0.01
According to Starpharma Holdings Limited's latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.02, a decrease compared to its 2024 EPS of $-0.01.
EPS history for Starpharma Holdings Limited from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -39.50% |
| 2025 | $-0.02 | 17.16% |
| 2024 | $-0.01 | -49.81% |
| 2023 | $-0.03 | -3.26% |
| 2022 | $-0.03 | -26.40% |
| 2021 | $-0.04 | 35.87% |
| 2020 | $-0.03 | -1.78% |
| 2019 | $-0.03 | 36.41% |
| 2018 | $-0.02 | -35.22% |
| 2017 | $-0.03 | -30.87% |
| 2016 | $-0.05 | -2.13% |
| 2015 | $-0.05 | -3.29% |
| 2014 | $-0.05 | 187.57% |
| 2013 | $-0.02 | -67.56% |
| 2012 | $-0.05 | 31.90% |
| 2011 | $-0.04 | 64.58% |
| 2010 | $-0.02 | 32.60% |
| 2009 | $-0.02 | -55.20% |
| 2008 | $-0.04 | 6.32% |
| 2007 | $-0.04 | -10.17% |
| 2006 | $-0.04 | -18.50% |
| 2005 | $-0.05 | 38.77% |
| 2004 | $-0.04 | 2,776.92% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | -100.00% |
| 2001 | $-0.02 | 102.52% |
| 2000 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -129,521.49% |
US
|
|
| $-7.07 | 58,329.75% |
US
|
|
| $-5.29 | 43,619.01% |
AU
|
|
| $12.88 | -106,547.11% |
BE
|
|
| $21.56 | -178,281.82% |
NL
|
Questions about Starpharma Holdings Limited's earnings per share (EPS)
What is Starpharma Holdings Limited's earnings per share (EPS)?
Starpharma Holdings Limited's earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was Starpharma Holdings Limited's earnings per share (EPS) in 2025?
In 2025, Starpharma Holdings Limited's earnings per share (EPS) was $-0.02, compared with $-0.01 in 2024.
How has Starpharma Holdings Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Starpharma Holdings Limited's earnings per share (EPS) was highest in 2024 ($-0.01) and lowest in 2021 ($-0.04).
How does Starpharma Holdings Limited's earnings per share (EPS) compare with similar companies?
Starpharma Holdings Limited's earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.